Inflammatory Mechanisms Articles & Analysis
10 news found
Unfortunately, these therapies do little to address the underlying inflammatory mechanisms that drive PAH or significantly improve survival rates. ...
It is has been effective in preclinical studies in a broad range of conditions including, hemorrhagic shock, traumatic brain injury, stroke, sickle cell anemia and a host of other conditions. The primary mechanism of action of VitalHeme is dismutation of vascular superoxide, in which it outperforms native superoxide dismutase. Its secondary mechanism is blocking ...
“Preclinical studies from our ILB program have also demonstrated the drug’s unique ability to enhance endogenous repair mechanisms and rebalance inflammatory responses providing a new, potentially invaluable mechanism of action in the treatment of neurodegenerative diseases” ...
Pre-clinical testing of AlucentNVS in animal studies has shown acute and long-term safety and patency without the pro-inflammatory and mechanical risks of placing a rigid foreign implant into the blood vessel. ...
PROPEL Contour incorporates a unique hourglass design that conforms to the sinus openings that delivers an advanced corticosteroid with anti-inflammatory properties and mechanical support to help improve surgical outcomes. ...
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. ...
The treatment response appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (neuro)inflammatory processes. The deranged neuronal function associated with the oxidative/nitrosative stress and mitochondrial dysfunction characterized by the pathophysiological progress of neurodegenerative conditions such as ALS1 ...
Our evidence also found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders. ...
” Pre-clinical testing of AlucentNVS in animal studies has shown acute and long-term safety and patency without the pro-inflammatory and mechanical risks of placing a rigid foreign implant into the blood vessel. ...
“FDA approval to commence human clinical testing allows us to move this revolutionary therapy into PAD patients, many of whom are in acute need of a better and more durable alternative to currently available treatments,” said Myles Greenberg, M.D., Alucent’s CEO Preclinical testing of NVS in animal studies has shown acute and long-term safety and patency without the ...